2020
BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies
Mckean M, Bendell J, Petrylak D, Powles T, Sonpavde G, Dickson A, Dosunmu L, Hennessy M, Jeffrey P, Rigby M, West T. BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies. Annals Of Oncology 2020, 31: s500-s501. DOI: 10.1016/j.annonc.2020.08.713.Peer-Reviewed Original Research
2006
Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants
Venner P, Ryan C, Petrylak D, Chatta G, Ruether J, Chi K, Curd J, Beer T. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants. Journal Of Clinical Oncology 2006, 24: 4505-4505. DOI: 10.1200/jco.2006.24.18_suppl.4505.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerSerious adverse eventsThromboembolic eventsDN-101Prostate cancerExact testMetastatic androgen-independent prostate cancerIncidence of TEPlacebo-controlled studyVDR knockout miceEffects of calcitriolFisher's exact testDocetaxel regimenPlacebo groupAdvanced malignanciesAdverse eventsVitamin DBaseline useEfficacy resultsGrade 3Study groupNatural anticoagulantsOral formulationKnockout micePatients